Northern Trust Corp Ardelyx, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Ardelyx, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 2,150,974 shares of ARDX stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,150,974

Previous 2,100,533 2.4%

Holding current value

$11.5 Million

Previous $14.5 Million 23.16%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.49 - $6.85 $226,480 - $345,520	50,441 Added 2.4%	2,150,974 $11.1 Million
Q3 2024 Nov 13, 2024	BUY	$5.28 - $7.57 $134,618 - $193,004	25,496 Added 1.23%	2,100,533 $14.5 Million
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $435,111 - $687,757	-73,873 Reduced 3.44%	2,075,037 $15.4 Million
Q1 2024 May 14, 2024	SELL	$6.05 - $9.74 $235,393 - $378,963	-38,908 Reduced 1.78%	2,148,910 $15.7 Million
Q4 2023 Feb 13, 2024	BUY	$3.29 - $6.64 $762,125 - $1.54 Million	231,649 Added 11.84%	2,187,818 $13.6 Million
Q3 2023 Nov 13, 2023	BUY	$3.3 - $4.83 $14,470 - $21,179	4,385 Added 0.22%	1,956,169 $7.98 Million
Q2 2023 Aug 11, 2023	BUY	$3.23 - $4.95 $4.78 Million - $7.33 Million	1,480,747 Added 314.36%	1,951,784 $6.62 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $272,221 - $486,544	101,575 Added 27.49%	471,037 $2.26 Million
Q4 2022 Feb 13, 2023	BUY	$1.22 - $2.85 $123,123 - $287,624	100,921 Added 37.58%	369,462 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $42,388 - $103,456	71,845 Added 36.53%	268,541 $320,000
Q2 2022 Aug 12, 2022	SELL	$0.51 - $1.17 $321,513 - $737,590	-630,419 Reduced 76.22%	196,696 $116,000
Q1 2022 May 13, 2022	BUY	$0.65 - $1.18 $4,218 - $7,658	6,490 Added 0.79%	827,115 $885,000
Q4 2021 Feb 08, 2022	SELL	$0.86 - $1.7 $19,316 - $38,183	-22,461 Reduced 2.66%	820,625 $903,000
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $28,181 - $181,292	-22,190 Reduced 2.56%	843,086 $1.11 Million
Q2 2021 Aug 13, 2021	BUY	$6.55 - $8.98 $264,770 - $362,998	40,423 Added 4.9%	865,276 $6.56 Million
Q1 2021 May 12, 2021	SELL	$6.1 - $7.69 $218,068 - $274,909	-35,749 Reduced 4.15%	824,853 $5.46 Million
Q4 2020 Feb 11, 2021	SELL	$5.05 - $7.1 $35,521 - $49,941	-7,034 Reduced 0.81%	860,602 $5.57 Million
Q3 2020 Nov 16, 2020	SELL	$5.25 - $7.08 $322,166 - $434,464	-61,365 Reduced 6.61%	867,636 $4.56 Million
Q2 2020 Aug 14, 2020	BUY	$5.37 - $8.11 $959,441 - $1.45 Million	178,667 Added 23.81%	929,001 $6.43 Million
Q1 2020 May 14, 2020	BUY	$4.35 - $8.79 $635,856 - $1.28 Million	146,174 Added 24.19%	750,334 $4.27 Million
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $216,808 - $424,903	51,255 Added 9.27%	604,160 $4.53 Million
Q3 2019 Nov 13, 2019	BUY	$2.15 - $6.28 $48,342 - $141,205	22,485 Added 4.24%	552,905 $2.6 Million
Q2 2019 Aug 13, 2019	BUY	$2.49 - $3.73 $35,644 - $53,394	14,315 Added 2.77%	530,420 $1.43 Million
Q1 2019 May 13, 2019	BUY	$1.88 - $3.35 $2,195 - $3,912	1,168 Added 0.23%	516,105 $1.45 Million
Q4 2018 Feb 12, 2019	SELL	$1.66 - $4.16 $1,092 - $2,737	-658 Reduced 0.13%	514,937 $922,000
Q3 2018 Nov 14, 2018	BUY	$3.75 - $4.65 $386,988 - $479,866	103,197 Added 25.02%	515,595 $2.24 Million
Q2 2018 Sep 18, 2018	BUY	$3.7 - $5.8 $9,124 - $14,302	2,466 Added 0.6%	412,398 $1.53 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $141,850 - $222,360	38,338 Added 10.32%	409,932 $1.52 Million
Q1 2018 May 09, 2018	SELL	$5.05 - $7.9 $10,599 - $16,582	-2,099 Reduced 0.56%	371,594 $1.88 Million
Q4 2017 Feb 14, 2018	SELL	$4.85 - $7.8 $70,708 - $113,716	-14,579 Reduced 3.75%	373,693 $2.47 Million
Q3 2017 Nov 13, 2017	BUY	$4.35 - $5.7 $1.69 Million - $2.21 Million	388,272	388,272 $2.17 Million

Others Institutions Holding ARDX

# of Institutions

233

Shares Held

150M

Call Options Held

1.54M

Put Options Held

3.08M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $824M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Ardelyx, Inc. Transaction History